rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NRSN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
      Nov 2Yahoo FinanceNRSN
      NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

      NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced that it has filed a patent application with the U.S. Patent and Trademark Office covering methods of treating traumatic brain injury (TBI) and related central nervous system injuries with the combination of ciprofloxacin and celecoxib, the active ingredients of PrimeC.

      Oct 19Yahoo FinanceNRSN
      NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
      Oct 13MorningstarNRSN
      NeuroSense Regains Nasdaq Bid Price Compliance, Appeals Market Value Delisting Notice

      Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailNRSN
      Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice
      Oct 2Yahoo FinanceNRSN
      NeuroSense Provides Update on Nasdaq Listing Compliance
      Oct 2Yahoo FinanceNRSN
      NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
      Sep 28Yahoo FinanceNRSN
      NeuroSense Provides Business Update and Progress for the First Half of 2026

      Targeting December 2026 NDS filing in Canada– Following completion of the Pre-New Drug Submission process and finalization of meeting minutes with Health Canada, NeuroSense is preparing an NDS for PrimeC in ALS and is targeting December 2026 for submission. Health Canada indicated no concerns with the proposed filing timeline and provided alignment...

      Sep 25NasdaqNRSN
      NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq

      Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailNRSN
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailNRSN
      This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
      Sep 3BenzingaNRSNOXY
      NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
      Aug 31MorningstarNRSN
      NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval
      Aug 31BenzingaNRSN
      12 Health Care Stocks Moving In Tuesday's After-Market Session
      Aug 25BenzingaAKANALECMRKRNRSNSYREVVOS

      This is the newest page. Registered accounts read further back.